Detail
Článek
Web zdroj
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Result of the first 12 months of treatment of macular edema complicating brvo in patients treated with ranibizumab

Lalinská L., Krásný J., Studený P., Veith M.

Jazyk angličtina Země Česko

Perzistentní odkaz   https://www.medvik.cz/link/bmc19000075

The aim of the study: Retrospective evaluation of the first 12 months treatment of macular edema in BRVO with ranibizumab based on anatomical and functional parameters. Methods: 54 eyes with macular edema complicating BRVO were included in the study, with an average initial best corrected visual acuity 4/16 ETDRS charts, an average central retinal thickness 512.3 μm, and in average 4 months till the beginning of treatment with ranibizumab. After 3 initial injections of 0.5 mg ranibizumab treatment was performed in pro re nata regimen, with adjuvant laser (grid laser photocoagulation) as an additional treatment option. The number of injections administered, the number of eyes where grid laser photocoagulation was provided, functional parameters as a letter gain and BCVA (eyes with final BCVA ≥ 4/8 ETDRS, final BCVA in according to initial BCVA) and anatomical parameters as a mean CRT and CRT ≤ 250 μm, respectively ≤ 300 μm were evaluated. Results: In the whole group, an average of 4.8 injections of ranibizumab were administered in the first 12 months. Grid laser photocoagulation was performed in 42 eyes: in 8 eyes prior to the beginning of treatment with ranibizumab, 7 eyes before and during the treatment, 29 eyes only during the treatment. The main gain of letters after 12 months of treatment was +16.5 letters, with 63¨% (n = 34) eyes earning ≥ 15 letters. In the whole group 72 % (n = 39) eyes achieved the resulting BCVA ≥ 4/8 ETDRS after 12 months of treatment. The eyes with initial BCVA ≥ 4/10 ETDRS resulted in BCVA ≥ 4/8 ETDRS in 96 % (n = 23 eyes) and 11 eyes even achieved BCVA ≥ 4/4. The mean CRT after 12 months of treatment was 290.3 μm, 33.3 % of eyes had final CRT ≤ 250 μm, and 64.8 % had final CRT ≤ 300 μm. Conclusion: When applying a relatively low number of injections in the first year of treatment with ranibizumab, the final best corrected visual acuity was very good at the end of the observation period, and its dependence on the initial best corrected visual acuity was confirmed. Satisfactory results of central retinal thickness were found as well.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19000075
003      
CZ-PrNML
005      
20210602022945.0
007      
cr|cn|
008      
190104s2018 xr cd fs 000 0|eng||
009      
AR
024    0_
$a 10.31348/2018/1/3-2-2018 $2 doi
040    __
$a ABA008 $d ABA008 $e AACR2 $b cze
041    0_
$a eng
044    __
$a xr
100    1_
$a Lalinská, Lucia $7 xx0228453 $u Department of Ophthalmology, Královské Vinohrady University Hospital and 3rd Faculty of Medicine, Charles University Prague
245    10
$a Result of the first 12 months of treatment of macular edema complicating brvo in patients treated with ranibizumab / $c Lalinská L., Krásný J., Studený P., Veith M.
520    3_
$a The aim of the study: Retrospective evaluation of the first 12 months treatment of macular edema in BRVO with ranibizumab based on anatomical and functional parameters. Methods: 54 eyes with macular edema complicating BRVO were included in the study, with an average initial best corrected visual acuity 4/16 ETDRS charts, an average central retinal thickness 512.3 μm, and in average 4 months till the beginning of treatment with ranibizumab. After 3 initial injections of 0.5 mg ranibizumab treatment was performed in pro re nata regimen, with adjuvant laser (grid laser photocoagulation) as an additional treatment option. The number of injections administered, the number of eyes where grid laser photocoagulation was provided, functional parameters as a letter gain and BCVA (eyes with final BCVA ≥ 4/8 ETDRS, final BCVA in according to initial BCVA) and anatomical parameters as a mean CRT and CRT ≤ 250 μm, respectively ≤ 300 μm were evaluated. Results: In the whole group, an average of 4.8 injections of ranibizumab were administered in the first 12 months. Grid laser photocoagulation was performed in 42 eyes: in 8 eyes prior to the beginning of treatment with ranibizumab, 7 eyes before and during the treatment, 29 eyes only during the treatment. The main gain of letters after 12 months of treatment was +16.5 letters, with 63¨% (n = 34) eyes earning ≥ 15 letters. In the whole group 72 % (n = 39) eyes achieved the resulting BCVA ≥ 4/8 ETDRS after 12 months of treatment. The eyes with initial BCVA ≥ 4/10 ETDRS resulted in BCVA ≥ 4/8 ETDRS in 96 % (n = 23 eyes) and 11 eyes even achieved BCVA ≥ 4/4. The mean CRT after 12 months of treatment was 290.3 μm, 33.3 % of eyes had final CRT ≤ 250 μm, and 64.8 % had final CRT ≤ 300 μm. Conclusion: When applying a relatively low number of injections in the first year of treatment with ranibizumab, the final best corrected visual acuity was very good at the end of the observation period, and its dependence on the initial best corrected visual acuity was confirmed. Satisfactory results of central retinal thickness were found as well.
650    _2
$a dospělí $7 D000328
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a senioři $7 D000368
650    _2
$a ženské pohlaví $7 D005260
650    12
$a okluze retinální žíly $x farmakoterapie $x komplikace $7 D012170
650    12
$a makulární edém $x etiologie $x farmakoterapie $7 D008269
650    12
$a ranibizumab $x aplikace a dávkování $x farmakologie $x terapeutické užití $7 D000069579
650    _2
$a klinická studie jako téma $7 D000068456
650    _2
$a injekce intravitreální $x metody $7 D058449
650    _2
$a výsledek terapie $7 D016896
650    _2
$a humanizované monoklonální protilátky $x aplikace a dávkování $x farmakologie $x terapeutické užití $7 D061067
650    _2
$a vaskulární endoteliální růstové faktory $x antagonisté a inhibitory $x terapeutické užití $7 D042442
650    _2
$a laserová koagulace $x metody $7 D017075
650    _2
$a retina $7 D012160
650    _2
$a zraková ostrost $x účinky léků $7 D014792
650    _2
$a statistika jako téma $7 D013223
653    00
$a centrální retinální tloušťka
653    00
$a zisk písmen
700    1_
$a Krásný, Jan, $d 1952- $7 mzk2008430515 $u Department of Ophthalmology, Královské Vinohrady University Hospital and 3rd Faculty of Medicine, Charles University Prague
700    1_
$a Studený, Pavel, $u Department of Ophthalmology, Královské Vinohrady University Hospital and 3rd Faculty of Medicine, Charles University Prague $d 1968- $7 xx0098109
700    1_
$a Veith, Miroslav $u Department of Ophthalmology, Královské Vinohrady University Hospital and 3rd Faculty of Medicine, Charles University Prague $7 xx0228135
773    0_
$t Czech and Slovak Ophthalmology $g Roč. 5, č. 2 (2018), s. 62-67 $w MED00194413
856    41
$u http://www.cs-ophthalmology.cz/en/journal/2018/2/3 $y plný text volně přístupný
910    __
$a ABA008 $b online $y p $z 0
990    __
$a 20190104132740 $b ABA008
991    __
$a 20210602022944 $b ABA008
999    __
$a ok $b bmc $g 1363068 $s 1038187
BAS    __
$a 3 $a 4
BMC    __
$a 2018 $b 5 $c 2 $d 62-67 $m Czech and Slovak Ophthalmology $x MED00194413
LZP    __
$c NLK189 $d 20210531 $a NLK 2019-01/pk

Najít záznam

Citační ukazatele

Nahrávání dat ...